Generation Bio | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.594 M

Revenue: As of FY2025 Q3, the actual value is USD 1.594 M, beating the estimate of USD 550 K.

EPS: As of FY2025 Q3, the actual value is USD -0.82, beating the estimate of USD -9.34.

EBIT: As of FY2025 Q3, the actual value is USD -7.896 M.

Collaboration Revenue: $1.6 million for the three months ended September 30, 2025, compared to $7.6 million for the same period in 2024. For the nine months ended September 30, 2025, collaboration revenue was $11.1 million, compared to $15.7 million for the same period in 2024.

Research and Development Expenses: $21.6 million for the three months ended September 30, 2025, compared to $15.1 million for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $52.5 million, compared to $45.8 million for the same period in 2024.
General and Administrative Expenses: $12.2 million for the three months ended September 30, 2025, compared to $9.2 million for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $28.7 million, compared to $29.1 million for the same period in 2024.
Net Loss: $5.5 million for the three months ended September 30, 2025, compared to $15.3 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $41.2 million, compared to $110.3 million for the same period in 2024.

Net Cash Used in Operating Activities: - $97.9 million for the nine months ended September 30, 2025, compared to - $72.8 million for the same period in 2024.
Net Cash Provided by Investing Activities: $43.4 million for the nine months ended September 30, 2025, compared to $24.2 million for the same period in 2024.
Net Cash Provided by Financing Activities: $0.1 million for the nine months ended September 30, 2025, compared to $0.1 million for the same period in 2024.

Gain on Lease Termination: $25.5 million for the three months ended September 30, 2025, and $23.8 million for the nine months ended September 30, 2025, due to the settlement agreement with the landlord.

Core Business Focus: Generation Bio Co. is exploring strategic alternatives to maximize shareholder value, including potential acquisitions, mergers, business combinations, or other transactions. The company has implemented a strategic restructuring, resulting in a 90% reduction in workforce by the end of October 2025, with expected costs of $12.0 million to $15.0 million related to severance and retention payments and employee benefit costs.
Non-Core Business: The company is winding down its manufacturing and research and development efforts and is currently exploring strategic options for its assets.